|
tbar.gif
Click
here to
submit entries
|
|
|
Lilly,
Transition Therapeutics Ink Diabetes Deal
|
March
13, 2008--Transition Therapeutics
is granting Eli Lilly the exclusive worldwide rights to develop and
commercialize its gastrin-based therapies, including the lead compound
TT-223, which is currently in early Phase II testing for the treatment of
diabetes. Transition will receive a $7 million upfront payment and may
also receive up to $130 million in potential development and sales
milestones, as well as royalties on sales of gastrin-based therapies if
any product is successfully commercialized. Transition
Therapeutics
|
|
|
Genstruct: Patience, Persistence, and Payoff
By John Russell |
|
Finding the right business model for systems biology (SB) technology providers has been challenging — that’s hardly a new theme in biotech.
Click
here
|
|
|
